Cipla's 'core' growth offsets weak show in US, Covid portfolio

Contributing over 40% to total revenues, domestic market sales grew 16% on a high base of Covid-led drug sales. Sustained growth in the company's core therapies such as respiratory and urology compensated for the normalising contribution of the Covid portfolio.

via Economictimes

No comments